XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
| Status: | Completed |
|---|---|
| Conditions: | Angina, Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 3/3/2019 |
| Start Date: | November 2010 |
| End Date: | January 2017 |
This is a prospective, observational, single-arm, open-label, multicenter, postapproval
registry study in China. The purpose of this study is to:
- Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of
real-world patients receiving the XIENCE V EECSS during commercial use
- Evaluate patient compliance to dual antiplatelet therapy (DAPT)
registry study in China. The purpose of this study is to:
- Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of
real-world patients receiving the XIENCE V EECSS during commercial use
- Evaluate patient compliance to dual antiplatelet therapy (DAPT)
Inclusion Criteria:
- The patient or patient's legally-authorized representative agrees to participate in
this study by signing the Ethics Committee-approved informed consent form (ICF).
- Only XIENCE V stent(s) is/are implanted into the coronary vasculature during the index
procedure.
Exclusion Criteria:
- The inability to obtain a signed ICF
We found this trial at
1
site
Click here to add this to my saved trials
